KRAS P.G12C
Clinical trials for KRAS P.G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS P.G12C trials appear
Sign up with your email to follow new studies for KRAS P.G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets tough pancreatic cancer gene mutation
Disease control Recruiting nowThis study tests a new drug called JAB-21822 (Glecirasib) in people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug can shrink tumors and how safe it is. About 88 participants will take the drug daily, …
Matched conditions: KRAS P.G12C
Phase: PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for lung cancer patients with hard-to-treat gene mutation
Disease control Recruiting nowThis study tests a pill called sotorasib in people with stage III lung cancer that has a specific KRAS G12C gene change and cannot have standard chemo-radiation. About 19 participants will receive the drug to see if it can delay cancer growth. The goal is to measure how long the …
Matched conditions: KRAS P.G12C
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New pill targets tough cancers with KRAS mutation in early trial
Disease control Recruiting nowThis study tests a new daily pill, D3S-001, for people with advanced solid tumors that have a specific change in the KRAS gene (called G12C). The goal is to see if the drug is safe and can shrink tumors. About 442 participants will take the drug alone or with other treatments.
Matched conditions: KRAS P.G12C
Phase: PHASE1, PHASE2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated May 07, 2026 18:41 UTC